Encouraging clinical data reported from Phase 1/2 trial of sepofarsen for LCA10
Initial clinical data from Phase 1/2 trial of QR-421a for Usher syndrome type 2 on track for Q1 2020
QR-1123 Investigational New Drug application active for autosomal dominant re
… $15.75 per share including full exercise of underwriters’ option to purchase 862,500 additional ordinary shares. Gross … oligonucleotide QR-110 for treatment of inherited retinal dystrophy in adults and children with LCA10 ○ Structure-based computational approach for optimizing oligonucleotides for A-to-I editing Presented at …
… robust clinical proof of concept in the early phase of our development program. I also want to thank the patients that … LCA10 compound heterozygous patient cells and homozygous optic cups in a dose dependent manner. Based on this data, … into pre-clinical development for the treatment of dystrophic epidermolysis bullosa (DEB). QR-313 is an RNA …
… financial statements, the potential exercise of share options is not included in the diluted earnings per share … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal in …
… the nasal potential difference (NPD). PQ-010-002 is an open label 28-day study of topical exposure of QR-010 in 16 CF patients, 8 homozygous (carrying two copies) for the ΔF508 mutation and 8 compound heterozygous …
… for QR-110 from the FDA. The planned Phase 1/2 open-label trial (PQ-110-001) will include approximately 6 … 6 adults (≥ 18 years) that have LCA 10 due to one or two copies of the p.Cys998X mutation. During the trial, patients … with expertise in genetic retinal disease in the US and Europe. The primary objective will be to assess safety and …
… financial statements, the potential exercise of share options is not included in the diluted earnings per share … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal in … Premium Equity settled Employee Benefit Reserve Option premium on convertible loan Translation Reserve …
Illuminate Phase 2/3 trial of sepofarsen expected to complete enrollment in Q1 2021; additional data from Phase 1/2 InSight extension study to be reported in H2 2021
Enrollment completed for QR-421a dosing cohorts and data from next Phase 1/2 interim
… ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results LEIDEN, The Netherlands & … financial statements, the potential exercise of share options is not included in the diluted earnings per share … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal in …